News & events

Upcoming events

See all upcoming events

Latest news

The latest test from Fujirebio’s gold standard Alzheimer panel, the INNOTEST® β-AMYLOID(1-40), is now CE marked

Fujirebio Europe announces having received the CE mark for its INNOTEST β-AMYLOID(1-40) Alzheimer test, an immunoassay kit for the quantification of β-Amyloid(1-40) in cerebrospinal fluid. With its CE version this marker can now be used for in vitro diagnostics in combination with the existing range of INNOTESTAlzheimer biomarkers for routine testing (Aβ1-42, total Tau, and p-Tau181P).

Read more

Fujirebio Europe launches Lumipulse® G Progesterone-N, a biomarker for high-risk pregnancy monitoring and a valuable aid in detection and management of various causes of infertility

Fujirebio Europe announces the addition of the Lumipulse G Progesterone-N assay to the existing fertility test portfolio for use on the CLEIA-based LUMIPULSE G600II and the LUMIPULSE G1200 immunoassay systems. Progesterone is a steroid hormone that is synthesized in the gonads and the adrenal glands; measurement of progesterone can be used as one of the indicators of luteal function  in the investigation of infertility and also placental function during pregnancy.

Read more

Fujirebio Europe launches the TENDIGO™ instrument for low throughput INNO-LIA® and INNO-LiPA® assay automation

Fujirebio Europe today announced the release of its new TENDIGO automate. The TENDIGO is a small, state-of-the-art, and cost-efficient instrument designed specifically for laboratories who seek to perform low throughput automation of Fujirebio’s gold standard strip-based INNO-LIA and INNO-LiPA assay portfolios. The instrument also allows for automated testing of other blot strips (open protocols).

Read more

Fujirebio Europe releases the Lumipulse® G HE4 assay dedicated to ovarian cancer therapy monitoring and as an aid in estimating the risk of epithelial ovarian cancer in women with pelvic mass

Fujirebio Europe today announced the release of its new Lumipulse G HE4 assay which will be available for testing on its CLEIA-based LUMIPULSE G systems, the LUMIPULSE G600II and the LUMIPULSE G1200. Lumipulse G HE4 is the first new biomarker for ovarian cancer management in more than 30 years1 after the initial launch by Fujirebio of the CA125 test (also available on the LUMIPULSE G series).

Read more

Veuillez confirmer que vous êtes un professionnel de la santé

Le contenu de ce site web est en partie réservé aux professionnels de santé qui sont directement impliqués dans la fourniture de services de soins de santé aux patients. Si vous êtes un professionnel de santé et que vous disposez de tous les droits d'accès, veuillez confirmer en cliquant sur le bouton 'oui'.

Choose your country or region

Once you have made this selection we will show you only the content that is relevant for your country. You can change this setting any time by clicking on the flag in the top toolbar of our website and choosing another country.
The content of this website is in part restricted to healthcare professionals who are directly involved in the provision of healthcare services to patients. If you are a health professional and you have full access rights, please check this box and confirm below.